(Q34820259)

4 August 2017

1 reference

title

Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors? (English)

1 reference

4 August 2017

main subject

acute coronary syndrome

1 reference

John W Eikelboom

1

0 references

author name string

John French

series ordinal

2

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

62

1 reference

4 August 2017

issue

13

1 reference

4 August 2017

page(s)

1839-1852

1 reference

Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans

4 August 2017

cites work

1 reference

12 December 2020

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

1 reference

12 December 2020

Modulating platelet function with selective thrombin inhibitors

1 reference

12 December 2020

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

12 December 2020

Argatroban: a synthetic thrombin inhibitor of low relative molecular mass

1 reference

12 December 2020

Hirudins: from leeches to man.

1 reference

12 December 2020

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

12 December 2020

Thrombin-specific inhibition by and slow cleavage of hirulog-1

1 reference

12 December 2020

Results from late-breaking clinical trials sessions at ACC '98. American College of Cardiology

1 reference

12 December 2020

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

12 December 2020

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

12 December 2020

New anticoagulant drugs

1 reference

12 December 2020

Effects of hirudin on activated partial thromboplastin time determined with ten different reagents

1 reference

12 December 2020

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

12 December 2020

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

1 reference

12 December 2020

Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group

1 reference

12 December 2020

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

12 December 2020

Biochemistry and biology of hirudin.

1 reference

12 December 2020

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

1 reference

12 December 2020

The development of hirudin as an antithrombotic drug

1 reference

12 December 2020

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial

1 reference

12 December 2020

The use of bivalirudin in patients with renal impairment.

1 reference

12 December 2020

Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis

1 reference

12 December 2020

Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.

1 reference

12 December 2020

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

1 reference

12 December 2020

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

12 December 2020

Biological rationale for the therapeutic role of specific antithrombins

1 reference

12 December 2020

Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.

1 reference

12 December 2020

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

Highly selective tripeptide thrombin inhibitors

1 reference

12 December 2020

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

1 reference

12 December 2020

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

12 December 2020

Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin

1 reference

12 December 2020

Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters

1 reference

12 December 2020

Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina

1 reference

12 December 2020

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

12 December 2020

Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis

1 reference

12 December 2020

Quantitative determination of hirudin in blood and body fluids

1 reference

12 December 2020

Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty

1 reference

12 December 2020

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

1 reference

12 December 2020

Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit

1 reference

12 December 2020

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

12 December 2020

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

12 December 2020

Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation

1 reference

12 December 2020

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

12 December 2020

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

12 December 2020

Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coron

1 reference

12 December 2020

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

1 reference

12 December 2020

A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

10.2165/00003495-200262130-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1038980970

0 references

1 reference